We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed at $8.42 in the latest trading session, marking a -1.86% move from the prior day. This change lagged the S&P 500's daily loss of 1.22%. Elsewhere, the Dow lost 0.98%, while the tech-heavy Nasdaq lost 1.35%.
The infectious disease drug developer's shares have seen a decrease of 0.58% over the last month, not keeping up with the Medical sector's gain of 4.11% and the S&P 500's gain of 1.56%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. The company's upcoming EPS is projected at $0.16, signifying a 6.67% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $125.77 million, up 3.11% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.82 per share and a revenue of $535 million, representing changes of +36.67% and +4.87%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 2.38% fall in the Zacks Consensus EPS estimate. As of now, Adma Biologics holds a Zacks Rank of #5 (Strong Sell).
Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 10.46. This denotes a discount relative to the industry average Forward P/E of 21.05.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 150, this industry ranks in the bottom 39% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know
Adma Biologics (ADMA - Free Report) closed at $8.42 in the latest trading session, marking a -1.86% move from the prior day. This change lagged the S&P 500's daily loss of 1.22%. Elsewhere, the Dow lost 0.98%, while the tech-heavy Nasdaq lost 1.35%.
The infectious disease drug developer's shares have seen a decrease of 0.58% over the last month, not keeping up with the Medical sector's gain of 4.11% and the S&P 500's gain of 1.56%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. The company's upcoming EPS is projected at $0.16, signifying a 6.67% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $125.77 million, up 3.11% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.82 per share and a revenue of $535 million, representing changes of +36.67% and +4.87%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 2.38% fall in the Zacks Consensus EPS estimate. As of now, Adma Biologics holds a Zacks Rank of #5 (Strong Sell).
Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 10.46. This denotes a discount relative to the industry average Forward P/E of 21.05.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 150, this industry ranks in the bottom 39% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.